Site Editor

David S. Ettinger, MD, FACP, FCCP


WCLC 2022: Nonregional Lymph Nodes and Prognosis in Stage IV NSCLC

By: Kayci Reyer
Posted: Friday, August 26, 2022

According to research presented at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer (WCLC) 2022 (Abstract OA11.03), patients with advanced non–small cell lung cancer (NSCLC) whose metastases are limited to distant lymph nodes may have a better prognosis than other patients with advanced disease. The study compared outcomes among patients with nodal, single-organ, or multiorgan metastases.

“Stage IV NSCLC patients presenting with only distant lymph node metastases may have a significant survival advantage compared to other stage IV patients, which can help guide shared decision-making and may support revision of the M1 stage subclassifications,” concluded Maureen E. Canavan, PhD, of the Yale School of Medicine, New Haven, Connecticut, and colleagues.

The study used the National Cancer Database to identify 113,756 patients who were diagnosed with stage IV disease between 2016 and 2018. Patient subgroups included those with single-organ (n = 58,712), multiorgan (n = 52,153), and nodal (n = 2,891) disease. The 3-year survival rate was 27.4% in the nodal group, 20.5% in the single-organ group, and 13.0% in the multiorgan group. Patients with nodal disease were more likely to develop squamous cell carcinoma and to undergo immunotherapy and chemotherapy. Patients with single- or multiorgan disease were more likely to receive radiation therapy.

Across all groups, the median age was 67 years, 46.5% of patients were female, and sociodemographic factors were comparable.

Disclosure: For full disclosures of the study authors, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.